drugset / Trial / NCT02046850

To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

NCT02046850

Phase 1 Completed 24 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

Study to assess the effect of Rifampicin on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Timeline

Start
2014-02
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg Oral
Subject Selumetinib Small molecule 75 mg Oral

Indications